From AEEA monomer to dimer

The Drug to Antibody Ratio (DAR) is a key quality attribute of antibody conjugated drugs (ADCs) that directly affects efficacy and toxicity. The ideal DAR is usually 2-4, but many efficient payloads such as MMAE and DM1 have strong hydrophobicity. When using short chain or single PEG linkers, DAR exceeding 4 leads to accelerated antibody aggregation and clearance. The introduction of AEEA-AEEA provides an effective solution to this problem.
Compared to a single AEEA linker, AEEA-AEEA doubles the PEG chain length and has stronger hydrophilicity. Each dimer unit contributes 4 ether bonds and 2 amide bonds, which can bind more water molecules and form a denser hydration layer. When multiple hydrophobic drugs are connected to the antibody surface through AEEA-AEEA, the hydration layer can effectively shield the hydrophobic interactions between drugs and prevent antibody aggregation. Experimental data shows that ADCs constructed using AEEA-AEEA maintain colloidal stability (aggregation rate<5%) even when DAR reaches 6-8, while the control using single AEEA shows significant precipitation when DAR>4.
The DAR regulation strategy refers to the pre linking of AEEA-AEEA to a drug in site directed coupling technology, and then reacting with engineered cysteine on the antibody. By adjusting the molar ratio of linker drug to antibody (usually 3:1 to 10:1), the DAR value can be precisely controlled. For example, a 2-fold excess can yield DAR2 product, a 4-fold excess can yield DAR4, and an 8-fold excess can achieve DAR6-8. HIC-HPLC or mass spectrometry can accurately determine the distribution of DAR. For tumor indications requiring high load, such as breast cancer with low HER2 expression and small cell lung cancer, AEEA-AEEA makes high DAR possible and significantly improves tumor killing effect. Preclinical studies have shown that the ADC of DAR6 increases tumor inhibition rate by about 40% compared to the ADC of DAR4 at the same dose, without significantly increasing toxicity.